Aktienanalyse zu Nasus Pharma Ltd (NSRX)NSRXNasus Pharma Ltd

Nasus Pharma Ltd. is an Israel-based pharmaceutical company. The Company develops and manufactures pharmaceutical products and intranasal powder-based drug delivery systems. Its proprietary microsphere technology is designed to enable non-invasive intranasal administration of medications for emergency and acute-care applications, including the treatment of anaphylaxis and opioid overdose. The Company's formulations are designed to support rapid drug absorption and administration without the use of injections. Nasus Pharma Ltd. focuses on the development of drug delivery solutions intended for use by healthcare professionals, caregivers, first responders, and other non-professional users. The Company's products aim to improve the accessibility and administration of critical medications in emergency situations. It operates in the Healthcare sector.

Nasus Pharma Ltd is a good buy right now due to its recent price increase of 35.31% over the last 20 days and a current RSI of 78.7, indicating strong momentum. The company has successfully raised $15 million to fund clinical trials, which enhances its financial stability. However, the main risk is the high current liabilities of $4.95 million compared to current assets of only $291,000 in Q2 2025, indicating potential liquidity issues in the short term.